ustekinumab

4 · 20 / page

Ask MedXY AI

Latest news

Tag

GastroenterologyustekinumabCrohn's disease

Ustekinumab Shows Short-Term Benefit for Fistulising Perianal Crohn's Disease in Small Randomized Trial

By MedXY|Jul 26, 2026

A randomized trial found ustekinumab significantly improved combined clinical and radiological remission at week 12 vs placebo in fistulising perianal Crohn's disease, though long-term outcomes were less clear.

Evaluating Dose Intensification Strategies for Ustekinumab in Crohn’s Disease: Insights from the REScUE Trial

Gastroenterologyclinical trialCrohn’s disease

ustekinumab

Latest news

Ustekinumab Shows Short-Term Benefit for Fistulising Perianal Crohn's Disease in Small Randomized Trial

Evaluating Dose Intensification Strategies for Ustekinumab in Crohn’s Disease: Insights from the REScUE Trial

The Dawn of the “No-Clinical-Trial” Era for Biosimilars: FDA’s Historic Ustekinumab Approval Shift

Early Control of Ulcerative Colitis and Its Impact on Long-Term Outcomes: Insights from the UNIFI Phase 3 Study